SavedAdd your journal

Journals / Tıp Araştırmaları Dergisi / 2012 / Cilt: 10 - Sayı: 2

The effect of tiotropium bromur on decrease of FEV1 and FVC for six months

Tiotropium bromür’ün altı aylık sürede FEV1 ve FVC azalmasına olan etkisi

Hanifi YILDIZ
HÜLYA GÜNBATAR
SELVİ AŞKER
Bünyamin SERTOĞULLARINDAN
Bülent ÖZBAY
Pages
39–44
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In our study, while we were expecting increased FEV 1 losses in COPD events, this increase, even it was statistically meaningless, implies that tiotropium decreases FEV1 losses in COPD events.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To research the effect of tiotropium, which is a long term effective anticolinergic agent, on respiratorial functions in COPD events.
📊
Key Findings & Data:Methods: The study was performed on a randomized prospective on a group of 21 patients (3 females, 18 males) that had COPD disease.
💡
Conclusion & Impact:Conclusion: In our study, while we were expecting increased FEV 1 losses in COPD events, this increase, even it was statistically meaningless, implies that tiotropium decreases FEV1 losses in COPD events.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To research the effect of tiotropium, which is a long term effective anticolinergic agent, on respiratorial functions in COPD events. Methods: The study was performed on a randomized prospective on a group of 21 patients (3 females, 18 males) that had COPD disease. The basal FEV1 and the pre dose FEV 1 values that had been measured after 6 months of tiotropium usage were compared. Results: Age average was 57.4 ±11.Basal FEV 1 average was 1.39 ± 0.37 (% 47.1 ± 13.7) and the pre dose FEV 1 average after 6 months was 1.44 ± 0.50 (49.8 ± 14.8) (p> 0.005). Basal FVC average was 2.28 ± 0.7 (61 ± 18) and the pre dose FVC average after 6 months was 2.32 ± 0.7 ( 65.9 ± 18 ) (p> 0.005). The improve effort dispnea was obtained from questioning dyspnea of all patients. A statistically meaningless increase was determined after comparing the basal FEV1 , FVC to the pre dose FEV 1 and FVC values measured after 6 months tiotropium usage. Conclusion: In our study, while we were expecting increased FEV 1 losses in COPD events, this increase, even it was statistically meaningless, implies that tiotropium decreases FEV1 losses in COPD events.

Özet

Amaç: Uzun etkili, günde tek doz kullanılan bir antikolinerjik ajan olan tiotropiumun KOAH’lı olgularda 6 ay boyunca solunum fonksiyonları üzerine olan etkisi incelenecektir. Metodlar: Çalışma Göğüs Hastalıkları polikliniğine başvuran, çalışmaya katılmayı kabul eden, 21 KOAH’lı olgu üzerinde prospektif olarak yapıldı. Çalşmaya katılan hastaların bazal ve 6 ay sonraki doz öncesi solunum fonksiyon testleri değerlendirildi. Çalışmaya alınan tüm hastalar günde tek doz 18 μgr tiotropium aldı. Bazal ve 6 ay sonraki doz öncesi FEV 1 ( İlacın ilk kullanımından 23–24 saat sonraki FEV1 ) değerleri karşılaştırıldı. Çalışmaya alınan olguların bazal ve 6 ay sonra günlük aktivitelerindeki efor dispne yakınması sorgulandı. Bulgular: Çalışmaya alınan olguların bazal FEV 1 (Forced Expiratory Volume in 1 second) ortalaması 1.39 ± 0.37 lt / sn (% 47,1 ± 13,7), 6 ay sonrası doz öncesi FEV 1 ortalaması 1.44 ± 0.50 lt / sn (%49,8 ± 14,8) (p> 0.005). Bazal FVC (Forced Vital Capacity) ortalaması 2.28 ± 0,7 lt ( %61 ± 18), 6 ay sonrası doz öncesi FVC ortalaması 2.32 ± 0,7 lt ( %65,9 ± 18 ) (p> 0.005). Bazal FEV 1 /FVC ortalaması (% 56±9,3), 6 ay sonrası FEV 1 /FVC ortalaması (%57,28 ± 11,4) (p> 0.005) bulundu. Olguların bazal ve 6 ay tiotropium kullanımı sonrası ölçülen doz öncesi FEV 1 , FVC, FEV 1 /FVC ortalamaları karşılaştırıldığında ististatistiksel anlamlı olmayan artışlar tespit edildi. Çalışmaya katılan tüm hastaların sorgulamayla kendilerini daha iyi hissettikleri izlendi. Sonuç: KOAH’lı olgularda zamanla artan FEV 1 kayıpları beklenirken istatistiksel olarak anlamsız da olsa, altı aylık takipte bu artışın olması Tiotropiumun KOAH’lı olgularda uzun süreli kullanımında zamanla artan FEV 1 kayıplarını ve efor dispnesini azalttığını desteklemektedir.

🔖

Cite This Article

YILDIZ, H., GÜNBATAR, H., AŞKER, S., SERTOĞULLARINDAN, B., ÖZBAY, B. (2012). The effect of tiotropium bromur on decrease of FEV1 and FVC for six months. Tıp Araştırmaları Dergisi, Cilt: 10 - Sayı: 2, 39–44. https://ajindex.com/articles/361720

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Dusser D, Bravo M-L and Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547–555.
  2. Appleton S, Jones T, Poole P, Pilotto L, Adams R, Lasserson TJ, Smith B, Muhammad J. Ipratropium bromide versus long-acting beta–2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006 Jul 19;3:CD006101. Review. Hodder R, Ketsen S, Menjoge S, Viel K Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids International Journal of COPD 2007; 2 (2):157–67.
  3. Anzueto A, Tashkin D, Menjoge S, Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18:75-81.
  4. Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005;127:809-17. O’Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
  5. Celli B, Zu, Wallack R, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-1748.
  6. Tashkin D, Celli B, Senn S et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54.
  7. Littner MR, Ilowite JS, Tashkin DP et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable COPD. Am J Respir Crit Care Med 2000;161,1136-1142.
  8. Moita J, Barbara C, Cardoso J et al. Tiotropium improves FEV 1 in patients with COPD irrespective of smoking status. Pulm Pharmacol Ther 2008; 21:146-51.
  9. Tonnel AB, Perez T, Grosbois JM et al. Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD 1: Int J Chron Obstruct Pulmon Dis. 2008;3(2):301-10.
  10. Freeman D, Lee A, Price D. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CarE (SPRUCE) study, Respiratory Research 2007, 8.45 doi:10.1186/1465-9921-8-45.
  11. Hasegawa M, Makita H, Nasuhara Y et al. Relationship between improved airflow limitation and changes in airway calibre induced by inhaled anticholinergic agents in COPD. Thorax. 2009;64:332-8. Titova ON; Ignat'ev VA; Didur MD, et al. Effect of tiotropium bromide on exercise tolerance in patients with chronic obstructive pulmonary disease, Vopr